Available Technologies

ADDITIONAL FILTERS

292 available technologies

Cytotoxin Associated cagB, C Genes of H. Pylori

A cagB gene of H. pylori is provided. This nucleic acid can be the nucleic acid consisting of nucleotides 193 through 1158 in the sequence set forth as SEQ ID NO:1, which is an example of a native coding sequence for CagB. This nucleic acid can also be in a vector suitable for expressing a polypeptide encoded by the nucleic acid. A cagC gene of H. pylori is provided. This nucleic acid can be the isolated nucleic acid consisting of nucleotides 1170 through 3830 in the sequence set forth as SEQ ID NO:3, which is an example of a native coding sequence for CagC. This nucleic acid can also be in a vector suitable for expressing a polypeptide encoded by the nucleic acid. Isolated nucleic acids that specifically hybridize with cagB and cagC are provided. CagB and CagC are associated with peptic ulceration and other clinical syndromes in humans infected with strains of H. pylori that express it.

Characterized BRCA1 and BRCA2 Proteins and Screening and Therapeutic Methods Based on Characterized BRCA1 and BRCA2 Proteins

Therapeutic methods for the treatment of prostate cancer are described. The methods include a gene therapy method for prostate cancer using the BRCA family of genes, including the BRCA1 and BRCA2 genes. The BRCA family of gene products inhibit the growth and tumorigenesis of prostate cancer cells. Therapeutic methods using the BRCA family of gene products are also described.

Amphiphilic Polyamine Compounds

In accordance with the present invention, there are provided amphiphilic polyamine compounds and derivatives thereof having the property of promoting transfection of polynucleotides and polypeptides into cells, and formulations comprising said compounds.

Trypterygium Wilfordii II Hook F Extracts as Therapeutic Agents

The present invention provides for the use of Tripterygium wilfordii Hook F extracts and purified components thereof in the treatment of inflammation or an immune disorder with concomitant lack of steroidal effect. Extracts of this plant (T2) bound to the glucocorticoid receptor and competitively inhibited glucocorticoid mediated cellular processes, such as dexamethasone binding to the glucocorticoid receptor, glucocorticoid mediated activation of target genes, dexamethasone dependent cellular growth, with concomitant inhibition of cyclooxygenase-2 induction and inflammatory processes such as the production of prostaglandin E.sub.2. The T2 extract components triptolide and tripdiolide were effective inhibitors. The particular advantage provided by the methods herein is the treatment or prevention of inflammation and the concomitant lack of steroidal agonist effects and NSAID side effects. Conditions treatable by the present methods include inflammation and immune disorders including autoimmune disease.

Methods of Purifying and Differentiating Spermatogonial Stem Cells

The invention relates to cell proliferation, cell differentiation, male infertility, male fertility and to compositions and methods involved therein. Also methods of culturing spermatogonial stem cells with bone morphogenetic protein 8 are disclosed.

Substituted Dicinnamoylquinides and Their Use in Augmentation of Adenosine Function

A novel method of treating human diseases using natural products found in roasted coffee. The use of natural products or derivatives thereof would permit the general public to improve their health without having to use prescription drugs.

Assay for Novel Serotonin Transporter Blockers

The mutant SERTs we have developed can provide for a platform to screen for novel modes/molecules interrupting SERT function. As SERT blockers are effective antidepressants, this strategy can lead to novel antidepressant medications. It may also be useful in development of animal models to test antidepressant action in vivo.

MMP-7 Null Mice

The only MMP-7-null mouse that has been generated. Used to determine biological function of MMP-7. Mice have been used in more than 10 publications at this point, and will be distributed by a commercial vendor in the near future.

HEK-293 Cell Line Containing the Human Norepiephrine Transporter cDNA (Norepi Cell Line)

Mouse Fc-FGF-1

We produced a plasmid containing the Fc portion of mouse IgGl (Fc) coupled to human fibroblast growth factor 1 (FGF-1). The plasmid was transformed into E. coli to express the fusion protein. The fusion protein was purified on a heparin sepharose column which has high affinity for the FGF portion of the fusion protein. The purpose of making this protein was to be able to identify cells that express receptors for FGF using flow cytometry.There are multiple fluorochrome labeled antibodies to mouse IgGl. When the fusion protein is bound to FGF receptors on cells, the Fc portion is on the surface of the cells and can be detected by fluorochrome labeled antibodies to mouse IgGl. Therefore, cells that express FGF receptors and bind the fusion protein can be detected by flow cytometry or immunofluorescence.

Genetic Mutation Underlying Orthostatic Intolerence and Diagnostic, Therapeutic and Screening Methods Related Thereto

The mutation allows for the first genetic test to be conducted for one form of chronic fatigue or mitral valve prolapse which we describe as orthostatic intolerance or postural tachycardia syndrome (POTS). The technology allows for the development of this test and the development of other tests in the same gene at other loci that may contribute to similar illnesses. The awareness of a phenotype associated with the mutation in the antidepressant-sensitive NET allows for evaluation of the role of the NET gene in mental illness and thus the development of genetic tests for increased susceptibility to mental and autonomic illnesses. This is the first neurotransmitter transporter gene defect that has been shown to be linked to a disorder. The precedent act opens the door for screening for other genetic mutations in genetically related transporters such as the serotonin transporter or dopamine transporter. These latter transporters have been implicated in depression anxiety, pscyhostimulant abuse (cocaine/amphetamine) and attention-deficit disorder. Our work allows for genetic inspection of transporter genes associated with these disorders. Our work may also allow for an examination of whether circulating antibodies against the NE transporter are contributory to OI or other chronic fatigue disorders.

EP4 Transgenic Mice

mCRTH2 Expression Construct

Featured Video

2012 Highlights

A motion graphic video describing operational improvements and successes of FY2012. Click here for a full PDF report.